Feed Top Reports Pricing

⌘K

12:21:53·13d

ANALYSTRating

Raymond James resumed coverage on Jazz Pharma with a new price target

JAZZ· Jazz Pharmaceuticals plc

Health Care

Original source

Companies

JAZZ
Jazz Pharmaceuticals plc
Health Care

Recent analyst ratings

Apr 10UpdateRaymond James$227.00
Feb 27UpdateBarclays$224.00
Nov 24UpdateUBS$188.00
Jul 15UpdateDeutsche Bank$152.00
Mar 7UpdateUBS$179.00
Feb 26UpdateCantor Fitzgerald-

Related

PR2d
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
PR2d
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
PR14d
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
INSIDER20d
SEC Form 4 filed by Cozadd Bruce C
PR22d
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
SEC22d
SEC Form 144 filed by Jazz Pharmaceuticals plc
SEC27d
Amendment: SEC Form SCHEDULE 13G/A filed by Jazz Pharmaceuticals plc
PR30d
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022